Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis.

Using a meta-analysis of randomized controlled trials (RCTs), this study aimed to investigate the efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia.